The Hidden Costs Of Running A Biotech Company – Venture Capital Dispatch – Business Exchange


Heavy Upfront Investment in R&D

Heavy Upfront Investment in R&D

Here’s a thought:  To help recoup the high upfront investment the VCs and angel investors make for startup biotech firms, should biotech (and pharma) better  leverage their heft R&D investment by parallel pathing a related OTC offering?  This can also help to offset the low probability of success for stage 1 drugs.
The Hidden Costs Of Running A Biotech Company – Venture Capital Dispatch – Business Exchange.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s